ClinicalTrials.gg
Active, not recruitingNCT06317636PEAKUpdated Oct 2, 2025

Propofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression

A Phase 4 interventional study of Ketamine and Normal saline in Chronic Pain and Depression, sponsored by Stanford University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Stanford University · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies testing ketamine in Chronic Pain — 4 open to participants now, 5 under way, 1 of them phase 3. Ketamine · Chronic Pain.

Planned enrollment
17th of 32
40 · median 44
Started
2025
the only one that year
Phase 4
8 of 32
none open now
Registered
29th of 32
by date
Lead sponsor
2 of 32
Stanford University

Among the 32 studies testing ketamine in Chronic Pain, this one is the 17th largest by planned enrollment, is the only one that started in 2025, is one of 8 in phase 4, and was the 29th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

4 of the 32 studies testing ketamine in Chronic Pain are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About ketamine

Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing ketamine in Chronic Pain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare ketamine to a placebo when given as a single infusion during IV sedation in adults with chronic pain and depression. We do not know whether ketamine will be more effective than placebo under these circumstances.

This study aims to:

  • Evaluate whether placebo is non-inferior to ketamine in treating chronic pain and depression, when delivered under propofol sedation
  • Confirm that propofol sedation is a safe way to keep participants blinded to treatment
  • Assess patients' comfort with the sedation process to improve future studies
  • Explore whether patient expectations affects their pain and depression

Participants will:

  • Need to qualify for the study based on stringent medical criteria
  • Undergo sedation with propofol
  • Randomly receive either a ketamine or a placebo (saline) infusion during sedation
  • Complete several study assessments over 5-7 weeks
Read the detailed description

Ketamine is a dissociative anesthetic that has been in clinical use for more than 50 years. In addition to its well-known anesthetic and pain-relieving properties, ketamine has been found to have fast-acting antidepressant effects in patients with depression. However, the mechanisms underlying ketamine's ability to treat chronic pain and depression are poorly understood. A most basic question regarding ketamine's therapeutic mechanism is still unresolved: do patients need to consciously experience and recall ketamine's acute dissociative effects to receive lasting analgesic and antidepressant benefits? In this clinical trial, participants will receive either ketamine or a placebo when they are under sedation with propofol. A n=6 pilot feasibility phase will precede the fully-powered n=34 randomized controlled trial.

Enrollment for the n=6 pilot phase is complete as of 6/19/2025.

03

Conditions studied

  • Chronic Pain
  • Depression

Keywords

  • Chronic Pain
  • Depression
  • Ketamine
  • Propofol
  • Sedation
  • Psychotropic Drugs
  • Hypnotics and Sedatives
  • Dissociative Anesthetics
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 70 years old
  • Comfortable speaking and writing in English
  • Chronic pain present daily for at least 3 months
  • Currently experiencing depression
  • Able to comply with the study protocol and communicate with study personnel about adverse events and other information

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding
  • One or more health conditions that makes study unsafe or unfeasible, determined by study physicians
  • Regular use of medications that may have problematic interactions with the study drugs
  • Participating in another clinical trial which may conflict with this one
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Ketamine

    A one-time intravenous infusion of ketamine (0.5 mg/kg)

    Drug: Ketamine

  • Placebo comparator
    Saline

    A one-time intravenous infusion of normal saline

    Drug: Normal saline

Interventions

  • 0.5 mg/kg ketamine infused intravenously over 40 minutes

    Also known as: Ketalar

  • DrugNormal saline

    0.9% normal saline infused intravenously over 40 minutes

    Also known as: 0.9% NaCl

06

What researchers measure

Primary outcomes

  1. Pain intensity in the past 24 hours

    A numerical rating scale ranging from 0 (no pain) to 10 (worst possible pain) over the past 24 hours will be used to assess pain intensity.

    Time frame: screening; 1, 7, 14, 21 and 28 days after treatment

Secondary outcomes

  1. Depression Severity and Blinding

    The 16-item Quick Inventory of Depressive Symptomatology Self-Report will be used to assess the severity of depressive symptoms. Items are self-rated on a 4-point scale tailored to each depression-related symptom. Higher total scores indicate greater depression symptom severity. Blinding will be assessed by asking participants to guess which treatment they received and rate their certainty on a simple 0-100 scale.

    Time frame: screening; day of infusion pre-treatment; 7, 14, 21 and 28 days after treatment

Other outcomes

  1. Number and severity of adverse events related to sedation

    Adverse events (AEs) will be assessed through a combination of patient self-report, interviews by study staff, and surveillance of medical records by the research team. AEs will be graded by severity (1=mild, 2=moderate, 3=severe, 4=life threatening, and 5=death) and relatedness to the intervention (0=definitely unrelated, 1=unlikely, 2=possibly related, 3=probably related, 4 definitely related).

    Time frame: during treatment; day of infusion post-treatment; 1, 7, 14, 21 and 28 days after treatment

  2. Side effects related to ketamine

    The Ketamine Side Effect Tool (KSET) is a standardized questionnaire designed to systematically assess the side effects experienced during or after ketamine administration. It covers a range of potential adverse effects, including dissociative, cardiovascular, and psychotomimetic symptoms. Participants are asked to rate the severity of each adverse effect as 'Never', 'Mild', 'Moderate', or 'Severe'.

    Time frame: day of infusion post-treatment; 1, 7, 14, 21 and 28 days after treatment

  3. Proportion of participants who accurately recall intra-sedation events

    Participants will be interviewed by study staff using the modified Brice Questionnaire, a set of questions asked in sequence to determine if the participant remembers anything between the time of induction and their awakening.

    Time frame: day of infusion post-treatment

  4. Participant expectations

    Expectations will be measured by asking participants to rate how effective they expect their treatment will be using a visual analog sliding scale from 0 ("Not effective at all") to 100 ("Completely effective"). They will then be asked to rate their level of confidence on a scale from 0 to 100%.

    Time frame: screening; day of infusion post-treatment; 1, 7, 14, 21 and 28 days after treatment

  5. Pressure pain threshold

    A pressure algometer device applied to the upper trapezius muscle will measure the pressure pain threshold by applying a controlled, gradually increasing force until the participant reports pain.

    Time frame: day of infusion pre-treatment; day of infusion post-treatment

  6. Mechanical temporal summation

    Mechanical temporal summation will be measured by applying the blunt tip of a thin flexible filament to the back of the hand and the lumbar region. Participants will be asked report pain intensity on a sale from 0 to 100 after a single application and after 10 repeated applications.

    Time frame: day of infusion pre-treatment; day of infusion post-treatment

  7. Conditioned pain modulation

    Conditioned pain modulation (CPM) measures the ability of the nervous system to inhibit a painful stimulus in the presence of another aversive stimulus. In this study, participants will immerse one hand in cold water and undergo pressure pain threshold measurements in the opposite trapezius muscle before, during, and after immersion.

    Time frame: day of infusion pre-treatment; day of infusion post-treatment

  8. Number of painful body regions

    The CHOIR Body Map is a visual tool that allows individuals to indicate the location(s) of their pain on a human body outline.

    Time frame: screening; day of infusion pre-treatment; day of infusion post-treatment; 1, 7, 14, 21 and 28 days after treatment

  9. Pain interference

    The 8-item PROMIS Pain Interference Short Form assesses the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. Items are self-rated on a 5-point scale ranging from 1 ("Not at all") to 5 ("Very Much"). Raw score totals are converted to standardized T-scores, with a higher T-score representing greater pain interference.

    Time frame: screening; day of infusion pre-treatment; 7, 14, 21 and 28 days after treatment

  10. Change in pain medication utilization

    Participants are asked to rate how their pain medication usage has changed compared to before treatment

    Time frame: 1, 7, 14, 21 and 28 days after treatment

  11. Physical function

    The 20-item PROMIS Physical Function Short Form assesses the ability to carry out physical tasks and activities in one's daily life. Items are self-rated on a 5-point scale ranging from 1 ("Unable to do") to 5 ("Without any difficulty"). Raw score totals are converted to standardized T-scores, with a higher T-score representing better physical function.

    Time frame: screening; day of infusion pre-treatment; 7, 14, 21 and 28 days after treatment

  12. Sleep disturbance

    The 8-item PROMIS Sleep Disturbance Short Form assesses an individual's perception of their sleep quality. Items are self-rated on a 5-point scale ranging from 1 ("Not at all") to 5 ("Very much"). Raw scores are converted to standardized T-scores, with higher a T-score representing more severe sleep disturbance.

    Time frame: screening; day of infusion pre-treatment; 7, 14, 21 and 28 days after treatment

  13. Anxiety symptom severity

    The 7-item Generalized Anxiety Disorder (GAD-7) Scale assesses the severity of anxiety symptomsover the past two weeks. Items are self-rated on a 4-point scale ranging from 0 ("Not at all") to 3 ("Nearly every day"), reflecting the frequency of symptoms. Higher total scores indicate greater anxiety symptom severity.

    Time frame: screening; day of infusion pre-treatment; 14 and 28 days after treatment]

  14. Peace of mind

    The 7-item Peace of Mind Scale assesses an individual's overall sense of inner calm and contentment. Items are self-rated on a 5-point scale ranging from 1 ("Not at all") to 5 ("All of the time"). Higher total scores reflect a greater sense of peace of mind.

    Time frame: screening; day of infusion pre-treatment; 7 and 28 days after treatment

  15. Emotion regulation

    The 10-item Emotion Regulation Questionnaire assesses individual differences in the habitual use of cognitive reappraisal and expressive suppression strategies. Items are self-rated on a 7-point scale ranging from 1 ("Strongly disagree") to 7 ("Strongly agree"). Higher scores on the cognitive reappraisal subscale indicate a greater tendency to reinterpret situations to manage emotions, while higher scores on the expressive suppression subscale indicate a greater tendency to inhibit outward emotional expression.

    Time frame: screening; day of infusion pre-treatment; 7 and 28 days after treatment

  16. Anhedonia

    The 14-item Snaith-Hamilton Pleasure Scale measures an individual's capacity to experience pleasure from various activities over the past 2 weeks, the absence of which indicates anhedonia. Items are self-rated on a 4-point scale ranging from 0 ("Strongly disagree") to 3 ("Strongly agree"). Lower total scores indicate greater degree of anhedonia.

    Time frame: screening; day of infusion pre-treatment; 14 and 28 days after treatment

  17. Enrollment rate

    The total number of consented, eligible participants enrolled by the end of the study divided by the amount of time between date of opening enrollment and the date of consent from the last participant.

    Time frame: from date of opening enrollment to the date of consent from the last participant, assessed up to 60 months

  18. Consent fraction

    The proportion of patients who are contacted by study staff for recruitment who provide written informed consent to study procedures.

    Time frame: from date of opening enrollment to the date of consent from the last participant, assessed up to 60 months

  19. Participant Experience Survey

    Participants are asked at the end of the study to rate their experience with study procedures and to provide feedback for improvement.

    Time frame: through study completion, an average of 4 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Lii TR, Sikka P, Deverett B, Altirkawi OK, Heifets BD. Protocol and pilot results for a double-blind randomized placebo-controlled trial of ketamine under propofol sedation for chronic pain and depression. Pain Manag. 2026 Jun;16(6):603-613. doi: 10.1080/17581869.2026.2658080. Epub 2026 Apr 16. PubMed 41988848 ↗

Individual participant data

Plan to share: Yes — De-identified participant data, study outcomes, and data dictionaries

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Available upon request after publication of the trial's primary findings for up to 5 years.

Access criteria: Researchers must submit a brief proposal and statistical analysis plan for review and approval by the investigators and execute a data sharing agreement.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Nov 2026, 22 months after the start.

Of 50 non-industry phase 4 interventional studies under Chronic Pain, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 22 months is close to that.

Counting every sponsor, half of 52 studies reached it within 24 months; a quarter within 14 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2024
First posted
Mar 19, 2024
StartActual
Jan 28, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Oct 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06317636
Responsible party
Theresa Lii (Principal Investigator, Stanford University) — Principal investigator
First posted
Mar 19, 2024
Start date
Jan 28, 2025
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 2, 2025

Study contacts

Theresa Lii, MD, MS
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion